HP
HealthInvest Partners Portfolio holdings
AUM $234M
1-Year Return
10.88%
This Quarter Return
+5.31%
1 Year Return
+10.88%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$213M
AUM Growth
+$48.7M
(+30%)
Cap. Flow
+$46.8M
Cap. Flow
% of AUM
22.01%
Top 10 Holdings %
Top 10 Hldgs %
61.4%
Holding
41
New
3
Increased
28
Reduced
1
Closed
5
Top Buys
| 1 |
Merck
MRK
|
+$4.77M |
| 2 |
Alkermes
ALKS
|
+$4.7M |
| 3 |
Harmony Biosciences
HRMY
|
+$4.68M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$4.26M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$3.57M |
Top Sells
| 1 |
IQVIA
IQV
|
+$2.96M |
| 2 |
Molina Healthcare
MOH
|
+$2.82M |
| 3 |
Option Care Health
OPCH
|
+$1.51M |
| 4 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$688K |
| 5 |
MacroGenics
MGNX
|
+$609K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Eli Lilly
LLY
$666B
| $27.1M | 12.73% |
30,564
+3,420
| +13% | +$3.03M |
|
2
UnitedHealth
UNH
$316B
| $20.8M | 9.75% |
35,490
+3,810
| +12% | +$2.23M |
|
|
3
Merck
MRK
$203B
| $17.6M | 8.26% |
154,699
+41,965
| +37% | +$4.77M |
|
4
Thermo Fisher Scientific
TMO
$179B
| $13.6M | 6.4% |
22,012
+2,554
| +13% | +$1.58M |
|
5
Amgen
AMGN
$147B
| $9.33M | 4.39% |
28,965
+1,376
| +5% | +$443K |
|
6
Boston Scientific
BSX
$149B
| $8.9M | 4.18% |
106,172
-385
| -0.4% | -$32.3K |
|
7
AbbVie
ABBV
$379B
| $8.79M | 4.13% |
44,486
+8,868
| +25% | +$1.75M |
|
8
Stryker
SYK
$145B
| $8.48M | 3.98% |
23,460
+3,477
| +17% | +$1.26M |
|
9
Cencora
COR
$57.4B
| $8.23M | 3.87% |
36,544
+6,224
| +21% | +$1.4M |
|
10
Vertex Pharmaceuticals
VRTX
$101B
| $7.9M | 3.71% |
16,993
+1,898
| +13% | +$883K |
|
11
Regeneron Pharmaceuticals
REGN
$60.6B
| $7.39M | 3.47% |
7,028
+135
| +2% | +$142K |
|
|
12
Neurocrine Biosciences
NBIX
$14B
| $6.98M | 3.28% |
60,607
+36,977
| +156% | +$4.26M |
|
|
13
Alkermes
ALKS
$4.39B
| $6.62M | 3.11% |
236,610
+167,810
| +244% | +$4.7M |
|
|
ITCI
14
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.19M | 2.91% |
84,578
+48,737
| +136% | +$3.57M |
|
|
15
Harmony Biosciences
HRMY
$1.85B
| $6.08M | 2.86% |
151,875
+116,975
| +335% | +$4.68M |
|
16
UFP Technologies
UFPT
$1.58B
| $5.72M | 2.69% |
18,048
+8,248
| +84% | +$2.61M |
|
17
Mirum Pharmaceuticals
MIRM
$3.72B
| $5.39M | 2.54% |
138,321
+63,121
| +84% | +$2.46M |
|
18
DexCom
DXCM
$29.9B
| $3.6M | 1.69% |
53,757
+19,274
| +56% | +$1.29M |
|
19
Arcellx
ACLX
$4.13B
| $3.36M | 1.58% |
40,230
+17,734
| +79% | +$1.48M |
|
20
Ionis Pharmaceuticals
IONS
$9.82B
| $3.31M | 1.56% |
82,691
+42,000
| +103% | +$1.68M |
|
21
Cardinal Health
CAH
$36.1B
| $3.04M | 1.43% |
27,500
| – | – |
|
22
Amicus Therapeutics
FOLD
$2.4B
| $2.94M | 1.38% |
275,472
+127,265
| +86% | +$1.36M |
|
23
Merus
MRUS
$5.15B
| $2.53M | 1.19% |
50,687
+19,850
| +64% | +$992K |
|
24
Edwards Lifesciences
EW
$45B
| $2.41M | 1.13% |
36,505
| – | – |
|
25
NewAmsterdam Pharma
NAMS
$2.68B
| $2.31M | 1.08% |
138,983
+63,189
| +83% | +$1.05M |
|